Michael Makris on Non-Malignant Haematology
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”What do you call the specialty of “non-malignant haematology”?
Everybody agrees that non-malignant haematology is not a good term.
Our US colleagues, backed by ASH, have chosen to go with “Classical Hematology”.
I have discussed this with colleagues in the UK and Europe, and have not met a single haematologist who likes the term Classical Haematology.
We now have a new name proposed: Medical Haematology.
A paper in the British Journal of Haematology discusses this in detail, including why this term is preferred to Classical Haematology, and also how this is integrated with hospital medicine and the future of the specialty.
My personal view is that our specialty should be called Medical not Classical Haematology.”
Read the full article here.
Article: Medical haematology: Repositioning haematology at the centre of medicine
Authors: Cheng Hock Toh, Imelda Bates, Sue Pavord
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 14, 2026, 16:28Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
-
Mar 14, 2026, 16:26Rida Fatima: When The Body’s Most Vital Production Unit Stops Working
-
Mar 14, 2026, 16:16Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease
-
Mar 14, 2026, 16:05Simon Senanu: D-Dimer – A Small Fragment with Big Clinical Significance
-
Mar 14, 2026, 15:53Ney Carter: Key Advances in the 2026 ACC/AHA Guideline on the Management of Dyslipidemia
-
Mar 14, 2026, 15:45Nicole Odofin: The First Blood Drive Event at Channel 4
-
Mar 14, 2026, 15:41Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
-
Mar 14, 2026, 15:40Jecko Thachil: Anticoagulation in Patients With Metabolic-Associated Fatty Liver Disease